Skip to content
Screener

Discontinued — last reported Q2 '22

Operating margin at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-2,999.4%-637pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-569.7%-284pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
15.4%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-12%-5.7pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-103.9%-43.0pp
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-15.1%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$2.23B+417%
Enterprise value$2.03B

Profitability

See full
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Calculated from Palvella Therapeutics’s reported figures.

Based on trailing twelve months.

The source filing: Palvella Therapeutics’s 10-Q, filed August 4, 2022. Open the filing →

Filed
Aug 4, 2022, 4:21 PM EDT
Fiscal quarter
Q2 FY2022
Calendar quarter
Q2 2022
Accession
0001583648-22-000065

FAQ

What is Palvella Therapeutics's operating margin?
Palvella Therapeutics (PVLA) reported operating margin of -183.2% in Q2 2022.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.

Ask your AI about Palvella Therapeutics's operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude